All the news

Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ...

The US Food and Drug Administration last week granted accelerated approval for pembrolizumab (Keytruda), an immunotherapy drug known as a checkpoint inhibitor, for people with hepatocellular carcinoma (HCC). Over years or decades chronic hepatitis B ...

People with liver cirrhosis and their families need more information about their condition and prognosis and greater access to palliative care, a systematic review of studies on the needs of people with cirrhosis ...

Measuring liver stiffness in primary care using Fibroscan is feasible and detects numerous cases of undiagnosed but advanced liver fibrosis, Australian researchers report in the journal BMJ Open this month. Despite availability of direct-acting ...

Ramucirumab (Cyramza), a type of targeted therapy that slows tumour growth by blocking blood vessel formation, led to improved overall survival and delayed disease progression in people with hepatocellular carcinoma ...

Personalised immunotherapy reduces the risk of liver cancer recurrence and may lead to tumour regression, according to a pair of studies presented at the 2018 International Liver Congress last month in Paris. In ...